藥品市場規模、佔有率、成長分析、按分子、副產品、按類型、按疾病、按給藥方法、按處方、按年齡、按最終用途、按地區 - 行業預測，2024-2031 年

2022年全球藥品市場規模為2098.5億美元，從2023年的2224.4億美元成長到2031年的3545.4億美元，預計在預測期內（2024-2031年）將以6.0%的複合年成長率成長。

藥品被定義為用於醫療目的的含有藥物的產品，由於消費者健康意識的增強，需求正在迅速成長。這種趨勢在 COVID-19 大流行期間加速，負責疫苗開發的製藥公司不僅生存下來，而且在經濟不確定的情況下蓬勃發展，凸顯了該行業的彈性。隨著人們優先考慮自己的健康，藥品市場可望持續成長。我們對醫療保健解決方案的持續承諾強調了藥物在社會中的重要作用，並確保只要公共衛生需求持續存在，市場就會持續擴張。透過專注於創新和可及性，製藥業有望滿足未來消費者不斷變化的需求。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

藥品市場規模：依分子及複合年成長率（2024-2031）

• 市場概況
• 生技藥品和生物相似藥（大分子）
• 常規藥物（小分子）

醫藥市場規模：依產品及複合年成長率（2024-2031）

• 市場概況
• 品牌
• 非專利的

藥品市場規模：按類型及複合年成長率（2024-2031）

• 市場概況
• 處方箋
• 在商店

藥品市場規模：依疾病及複合年成長率（2024-2031）

• 市場概況
• 心血管疾病
• 癌症
• 糖尿病
• 感染疾病
• 神經系統疾病
• 呼吸系統疾病
• 自體免疫疾病
• 精神疾病
• 胃腸道疾病
• 女性健康疾病
• 遺傳和罕見遺傳疾病
• 皮膚病
• 肥胖
• 腎臟疾病
• 肝臟疾病
• 血液疾病
• 眼睛狀況
• 不孕症
• 內分泌疾病
• 過敏
• 其他

藥品市場規模：依給藥方式及複方年成長率（2024-2031）

• 市場概況
• 口服
• 局部的
• 胃腸外的
  • 靜脈
  • 肌肉注射
• 吸入
• 其他

藥品市場規模：依處方及複合年成長率（2024-2031）

• 市場概況
• 藥片
• 膠囊
• 注射
• 噴
• 暫停
• 粉末
• 其他處方

醫藥市場規模：依年齡及複合年成長率（2024-2031）

• 市場概況
• 兒童和青少年
• 成人
• 老年病

藥品市場規模：依最終用途及複合年成長率（2024-2031）

• 市場概況
• 醫院
• 診所
• 其他

醫藥市場規模及複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Pfizer（USA）
• Johnson & Johnson（USA）
• Roche（Switzerland）
• Novartis（Switzerland）
• Merck & Co.（USA）
• AbbVie（USA）
• Bristol Myers Squibb（USA）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）
• Sanofi（France）
• AstraZeneca（UK）
• Amgen（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Merck KGaA（Germany）
• Vertex Pharmaceuticals Incorporated（USA）
• Biogen（USA）
• Regeneron Pharmaceuticals, Inc.（USA）
• Alexion Pharmaceuticals, Inc.（USA）
• Astellas Pharma Inc.（Japan）

結論和建議

Global Pharmaceuticals Market size was valued at USD 209.85 billion in 2022 and is poised to grow from USD 222.44 billion in 2023 to USD 354.54 billion by 2031, growing at a CAGR of 6.0% during the forecast period (2024-2031).

Pharmaceuticals, defined as drug-containing products formulated for medical purposes, are witnessing a surge in demand, driven by increasing consumer awareness about health and wellness. This trend accelerated during the COVID-19 pandemic, where pharmaceutical companies responsible for vaccine development not only survived but thrived amidst economic instability, highlighting the sector's resilience. As individuals prioritize their health, the pharmaceutical market is poised for continued growth. The ongoing commitment to healthcare solutions underscores the essential role of pharmaceuticals in society, ensuring sustained market expansion as long as public health needs persist. With a focus on innovation and accessibility, the industry is well-positioned to meet the evolving demands of consumers in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmaceuticals Market Segmental Analysis

Global Pharmaceuticals Market is segmented by molecule, product, type, disease, administration, formulation, age, end use and region. Based on molecule, the market is segmented into biologics & biosimilars (large molecules) and conventional drugs (small molecules). Based on product, the market is segmented into branded and generic. Based on type, the market is segmented into prescription and OTC. Based on disease, the market is segmented into cardiovascular diseases, cancer, diabetes, infectious diseases, neurological disorders, respiratory diseases, autoimmune diseases, mental health disorders, gastrointestinal disorders, women's health diseases, genetic and rare genetic diseases, dermatological conditions, obesity, renal diseases, liver conditions, hematological disorders, eye conditions, infertility conditions, endocrine disorders, allergies and others. Based on administration, the market is segmented into oral, topical, parenteral, inhalations and other. Based on formulation, the market is segmented into tablets, capsules, injectable, sprays, suspensions, powders and other formulations. Based on age, the market is segmented into children & adolescents, adults and geriatric. Based on end use, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmaceuticals Market

One of the key drivers of the Global Pharmaceuticals market is the rising aging population. Recent data from the Bureau of Census highlights a growth in the demographic of individuals aged 65 and older, increasing from 8% in 2015 to 9% in 2021. This demographic shift results from improved living standards and an expanding global population, significantly altering the population structure in many nations. The United Nations projects a staggering 56% rise in individuals aged 60 and above from 2015 to 2030. As people live longer, age-related health issues are becoming more prevalent, putting enormous pressure on healthcare systems worldwide. This scenario creates a critical need for innovative pharmaceutical solutions, as advancements in nanotechnology and artificial intelligence offer promising avenues to develop new treatments. Consequently, the growing patient base directly fuels the demand for medical interventions, driving substantial growth in the pharmaceuticals market.

Restraints in the Global Pharmaceuticals Market

The global pharmaceuticals market faces significant restraints stemming from a shortage of skilled labor and the volatility of raw material costs. The development of new drugs necessitates specialized skill sets that are currently available only in select research organizations, leading to an inadequate workforce. Additionally, fluctuating raw material prices hinder market expansion, creating further challenges for pharmaceutical companies. Compounding these issues is a pronounced talent gap, as the skills possessed by the current workforce do not adequately align with the advanced requirements of biopharma production. Companies struggle to find expertise in critical areas like automation, computer science, and process modeling, hindering innovation and progress within the industry.

Market Trends of the Global Pharmaceuticals Market

The Global Pharmaceuticals market is experiencing a significant trend toward restructuring and recovery post-COVID-19, as companies adapt to the new normal. As the demand for innovative therapies surges, firms are pivoting their business models to enhance resilience against future disruptions. The pandemic catalyzed a shift to digital health solutions and telemedicine, prompting pharmaceutical companies to invest in technology and streamline operations. There is also an increased focus on supply chain diversification and sustainability practices. This evolving landscape presents opportunities for growth and collaboration, positioning the pharmaceutical sector for a robust rebound and long-term evolution in healthcare delivery and access.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pharmaceuticals Market Size by Molecule & CAGR (2024-2031)

• Market Overview
• Biologics & Biosimilars (Large Molecules)
• Conventional Drugs (Small Molecules)

Global Pharmaceuticals Market Size by Product & CAGR (2024-2031)

• Market Overview
• Branded
• Generic

Global Pharmaceuticals Market Size by Type & CAGR (2024-2031)

• Market Overview
• Prescription
• OTC

Global Pharmaceuticals Market Size by Disease & CAGR (2024-2031)

• Market Overview
• Cardiovascular Diseases
• Cancer
• Diabetes
• Infectious Diseases
• Neurological Disorders
• Respiratory Diseases
• Autoimmune Diseases
• Mental Health Disorders
• Gastrointestinal Disorders
• Women'S Health Diseases
• Genetic and Rare Genetic Diseases
• Dermatological Conditions
• Obesity
• Renal Diseases
• Liver Conditions
• Hematological Disorders
• Eye Conditions
• Infertility Conditions
• Endocrine Disorders
• Allergies
• Others

Global Pharmaceuticals Market Size by Administration & CAGR (2024-2031)

• Market Overview
• Oral
• Topical
• Parenteral
  • Intravenous
  • Intramuscular
• Inhalations
• Other

Global Pharmaceuticals Market Size by Formulation & CAGR (2024-2031)

• Market Overview
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations

Global Pharmaceuticals Market Size by Age & CAGR (2024-2031)

• Market Overview
• Children & Adolescents
• Adults
• Geriatric

Global Pharmaceuticals Market Size by End Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Others

Global Pharmaceuticals Market Size & CAGR (2024-2031)

• North America (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • USA
  • Canada
• Europe (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Molecule, Product, Type, Disease, Administration, Formulation, Age, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations